Ra Pharmaceuticals, which is developing small molecule therapies targeting rare blood disorders, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Cambridge, MA-based company was founded in 2008. It plans to list on the Nasdaq under the symbol RARX. Credit Suisse, Jefferies, BMO Capital Markets and SunTrust Robinson Humphrey are the joint bookrunners on the deal. No pricing terms were disclosed.
